WebSep 11, 2024 · CAMBRIDGE, Mass., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, announced today the U.S. Patent and Trademark Office (USPTO) issued a decision in an interference between the University of California, the University of Vienna, Emmanuelle Charpentier (CVC) and … WebApr 13, 2024 · CAMBRIDGE, Mass., April 13, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced the appointment of current Independent Director...
With the recent patent news, who owns CRISPR now?
WebMay 4, 2024 · Editas Medicine is developing EDIT-103 for the treatment of rhodopsin-associated autosomal dominant retinitis pigmentosa (RHO-adRP), a progressive form of retinal degeneration. EDIT-103 uses two... WebFeb 21, 2024 · Well, since the PTAB's decision, Editas' stock has gone up roughly 36% —from about $19 a share immediately prior to the judgment to, today, $26 a share. That represents a market cap increase of... ba property management saskatoon
What Is Dylan Jovine’s (“Cut & Paste”) CRISPR Biotech Pick?
WebApr 13, 2024 · Editas Medicine is the exclusive licensee of Broad Institute and Harvard University’s Cas9 patent estates and Broad Institute’s Cas12a patent estate for human … WebFeb 16, 2024 · Shares in Editas Medicine rose 30% after the U.S. Shares in Editas Medicine rose 30% after the U.S. patent office sided with the Broad Institute in the legal … WebSep 11, 2024 · CAMBRIDGE, Mass., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, announced today the … ba program syllabus